Los Angeles, CA – November 14, 2025 -   The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce its collaboration with the California Institute of Technology (Caltech) on a newly awarded $2.8 million Discovery Stage Research (DISC0) grant from the California Institute for Regenerative Medicine (CIRM).

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies. These innovative immunotherapeutic approaches are fundamentally designed to enhance specific stages of the cancer-immunity cycle, a conceptual framework that describes the sequential events required to mount effective anti-tumor immune responses. By strategically targeting critical phases including antigen release, presentation, T-cell priming, trafficking, infiltration, and cytotoxic execution, cancer vaccines aim to overcome immune resistance mechanisms and promote durable tumor regression.